
## Percival Degrava Sampaio-Barros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2319516/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatology, The, 2022, 4, e113-e124.	3.9	24
2	Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort. Rheumatology, 2022, 61, 3686-3692.	1.9	12
3	Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. Journal of Applied Physiology, 2022, 132, 682-688.	2.5	2
4	Inflammatory myopathies overlapping with systemic sclerosis: a systematic review. Clinical Rheumatology, 2022, 41, 1951-1963.	2.2	6
5	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1036-1043.	0.9	30
6	Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Seminars in Arthritis and Rheumatism, 2022, 55, 151987.	3.4	12
7	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 2022, 61, SI169-SI174.	1.9	9
8	Psoriatic arthritis mutilans: a descriptive study from a Brazilian tertiary center. Advances in Rheumatology, 2022, 62, 14.	1.7	0
9	Is exposure to environmental factors associated with a characteristic clinical and laboratory profile in systemic sclerosis? A retrospective analysis. Rheumatology International, 2021, 41, 1143-1150.	3.0	11
10	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature Medicine, 2021, 27, 1744-1751.	30.7	148
11	Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis. Advances in Rheumatology, 2021, 61, 4.	1.7	3
12	Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. Advances in Rheumatology, 2021, 61, 69.	1.7	7
13	Clinical and laboratory features of African-Brazilian patients with systemic sclerosis. Clinical Rheumatology, 2020, 39, 9-17.	2.2	13
14	The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019. Advances in Rheumatology, 2020, 60, 19.	1.7	16
15	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2020, 79, 193-201.	0.9	59
16	Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. Clinics, 2020, 75, e1870.	1.5	4
17	Acroosteolysis and bone metabolism parameters distinguish female patients with limited systemic sclerosis with and without calcinosis: a case control study. Clinical Rheumatology, 2019, 38, 3189-3193.	2.2	5
18	Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI. Advances in Rheumatology, 2019, 59, 23.	1.7	21

#	Article	IF	CITATIONS
19	Clinical and laboratory profile of juvenile-onset systemic sclerosis in a Brazilian cohort. Journal of Scleroderma and Related Disorders, 2019, 4, 43-48.	1.7	2
20	AB0707â€LTBI SCREENING IN SPONDYLOARTHRITIS PATIENTSPRIOR TO ANTI-TNF TREATMENT AND FOLLOW-I IN AN ENDEMIC AREA. , 2019, , .	JP	0
21	AB0685â€ACROOSTEOLYSIS AND BONE METABOLISM PARAMETERS DISTINGUISH FEMALE PATIENTS WITH LIMITED SYSTEMIC SCLEROSISWITH AND WITHOUT CALCINOSIS: A CASE CONTROL STUDY. , 2019, , .		0
22	Proposition of a novel animal model of systemic sclerosis induced by type V collagen in C57BL/6 mice that reproduces fibrosis, vasculopathy and autoimmunity. Arthritis Research and Therapy, 2019, 21, 278.	3.5	14
23	Systemic sclerosis induced by the use of cocaine: is there an association?. Rheumatology International, 2019, 39, 387-393.	3.0	12
24	Different ethnic background is associated with distinct clinical profiles in the spondyloarthritides in the North and South of Brazil. Clinical Rheumatology, 2019, 38, 195-203.	2.2	9
25	Eosinophilic fasciitis during pregnancy: case report and review of literature. Rheumatology International, 2018, 38, 525-529.	3.0	1
26	Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Advances in Rheumatology, 2018, 58, 40.	1.7	17
27	Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis. Rheumatology, 2018, 57, 1721-1725.	1.9	9
28	Survival of connective tissue disease associated pulmonary arterial hypertension. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 186.	0.8	1
29	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.9	1,220
30	Evaluation of Left Ventricular Diastolic Function by Echocardiography with Tissue Doppler in Systemic Sclerosis. Arquivos Brasileiros De Cardiologia, 2017, 109, 410-415.	0.8	4
31	miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Research and Therapy, 2016, 18, 155.	3.5	96
32	Low vitamin D serum levels in diffuse systemic sclerosis: a correlation with worst quality of life and severe capillaroscopic findings. Revista Brasileira De Reumatologia, 2016, 56, 337-344.	0.7	23
33	Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine (United States), 2016, 95, e5652.	1.0	72
34	IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Research and Therapy, 2016, 18, 52.	3.5	35
35	Radiographic Assessment of Psoriatic Arthritis (PsA). , 2016, , 173-187.		0
36	Systemic sclerosis and silica exposure: a rare association in a large Brazilian cohort. Rheumatology International, 2016, 36, 697-702.	3.0	24

#	Article	IF	CITATIONS
37	Quality of life in spondyloarthritis: analysis of a large Brazilian cohort. Revista Brasileira De Reumatologia, 2016, 56, 22-27.	0.7	3
38	Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE). Revista Brasileira De Reumatologia, 2015, 55, 48-54.	0.7	1
39	Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides. Revista Brasileira De Reumatologia, 2015, 55, 281-309.	0.7	1
40	Assessment of fatigue in a large series of 1492 Brazilian patients with Spondyloarthritis. Modern Rheumatology, 2014, 24, 980-984.	1.8	11
41	Adverse effects of TNF inhibitors in SpA: Are they different from RA?. Best Practice and Research in Clinical Rheumatology, 2014, 28, 747-763.	3.3	20
42	Patients with Systemic Sclerosis Present Increased DNA Damage Differentially Associated with DNA Repair Gene Polymorphisms. Journal of Rheumatology, 2014, 41, 458-465.	2.0	22
43	Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritides. Revista Brasileira De Reumatologia, 2014, 54, 33-37.	0.7	3
44	Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ). Clinical Rheumatology, 2014, 33, 699-706.	2.2	13
45	Seronegative Arthritis in Latin America: A Current Review. Current Rheumatology Reports, 2014, 16, 438.	4.7	13
46	Association of Interferon―and Transforming Growth Factor β–Regulated Genes and Macrophage Activation With Systemic Sclerosis–Related Progressive Lung Fibrosis. Arthritis and Rheumatology, 2014, 66, 714-725.	5.6	169
47	Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clinical Rheumatology, 2014, 33, 1093-1098.	2.2	56
48	Perfil do uso de drogas modificadoras de doença no Registro Brasileiro de Espondiloartrites. Revista Brasileira De Reumatologia, 2014, 54, 33-37.	0.8	4
49	Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritides. Revista Brasileira De Reumatologia, 2014, 54, 33-7.	0.8	2
50	Recomendações sobre diagnóstico e tratamento da artrite psoriásica. Revista Brasileira De Reumatologia, 2013, 53, 227-241.	0.8	18
51	SAPHO Syndrome. Rheumatic Disease Clinics of North America, 2013, 39, 401-418.	1.9	52
52	Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus. Neurological Sciences, 2013, 34, 1009-1013.	1.9	8
53	Artrite enteropática no Brasil: dados do registro brasileiro de espondiloartrites. Revista Brasileira De Reumatologia, 2013, 53, 452-459.	0.8	11
54	Recomendações sobre diagnóstico e tratamento da espondilite anquilosante. Revista Brasileira De Reumatologia, 2013, 53, 242-257.	0.8	22

#	Article	IF	CITATIONS
55	Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritis. Revista Brasileira De Reumatologia, 2013, 53, 452-459.	0.7	1
56	Recommendations for the management and treatment of systemic sclerosis. Revista Brasileira De Reumatologia, 2013, 53, 258-275.	0.7	1
57	Recommendations for the management and treatment of ankylosing spondylitis. Revista Brasileira De Reumatologia, 2013, 53, 242-257.	0.7	8
58	Recomendações sobre diagnóstico e tratamento da esclerose sistêmica. Revista Brasileira De Reumatologia, 2013, 53, 258-275.	0.8	9
59	HLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients. Disease Markers, 2013, 35, 73-78.	1.3	10
60	Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology, 2013, 52, 1520-1524.	1.9	36
61	Effect of Enthesitis on 1505 Brazilian Patients with Spondyloarthritis. Journal of Rheumatology, 2013, 40, 1719-1725.	2.0	35
62	An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. Clinical and Experimental Rheumatology, 2013, 31, 484-9.	0.8	20
63	Recommendations for the management and treatment of psoriatic arthritis. Revista Brasileira De Reumatologia, 2013, 53, 227-41.	0.8	7
64	Recommendations for the management and treatment of ankylosing spondylitis. Revista Brasileira De Reumatologia, 2013, 53, 242-57.	0.8	6
65	Survival, Causes of Death, and Prognostic Factors in Systemic Sclerosis: Analysis of 947 Brazilian Patients. Journal of Rheumatology, 2012, 39, 1971-1978.	2.0	85
66	Ethnic Influence in Clinical and Functional Measures of Brazilian Patients with Spondyloarthritis. Journal of Rheumatology, 2012, 39, 141-147.	2.0	22
67	Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. International Journal of Molecular Medicine, 2012, 30, 1473-1480.	4.0	35
68	Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America. Journal of Rheumatology, 2012, 39, 2315-2320.	2.0	44
69	Atividade sexual na espondilite anquilosante. Revista Brasileira De Reumatologia, 2012, 52, 887-891.	0.8	12
70	Gender characterization in a large series of Brazilian patients with spondyloarthritis. Clinical Rheumatology, 2012, 31, 687-695.	2.2	59
71	Epidemiology of Spondyloarthritis in Brazil. American Journal of the Medical Sciences, 2011, 341, 287-288.	1.1	29
72	Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1068-1073.	0.9	87

#	Article	IF	CITATIONS
73	Registries in systemic sclerosis: a worldwide experience. Rheumatology, 2011, 50, 60-68.	1.9	45
74	Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease. Journal of Rheumatology, 2011, 38, 1656-1660.	2.0	77
75	Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Annals of the Rheumatic Diseases, 2011, 70, 2144-2147.	0.9	76
76	Undifferentiated Spondyloarthritis: A Longterm Followup. Journal of Rheumatology, 2010, 37, 1195-1199.	2.0	91
77	HLA-G Expression in the Skin of Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 1230-1234.	2.0	33
78	Frequency of HLA-B27 and its alleles in patients with Reiter syndrome: comparison with the frequency in other spondyloarthropathies and a healthy control population. Rheumatology International, 2008, 28, 483-486.	3.0	22
79	Frequency of HLA-B27 alleles in Brazilian patients with psoriatic arthritis. Clinical Rheumatology, 2008, 27, 709-712.	2.2	27
80	Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients. Chest, 2007, 131, 217-222.	0.8	92
81	Pulmonary involvement in ankylosing spondylitis. Clinical Rheumatology, 2007, 26, 225-230.	2.2	69
82	Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatology International, 2006, 26, 1143-1146.	3.0	63
83	Prognostic factors of low bone mineral density in ankylosing spondylitis. Clinical Rheumatology, 2005, 24, 310-311.	2.2	5
84	Unusual association of systemic sclerosis and ankylosing spondylitis. Clinical Rheumatology, 2005, 24, 652-654.	2.2	7
85	Frequency of the HLA-B27 alleles in Brazilian patients with AS. Journal of Rheumatology, 2003, 30, 2512.	2.0	8
86	Undifferentiated spondyloarthropathies in Brazilians: importance of HLA-B27 and the B7-CREG alleles in characterization and disease progression. Journal of Rheumatology, 2003, 30, 2632-7.	2.0	14